Drug Type Small molecule drug |
Synonyms Nalbuphine hydrochloride (USAN), EN-2234A, NSC-757829 + [8] |
Action agonists, antagonists |
Mechanism κ opioid receptor agonists(Kappa opioid receptor agonists), μ opioid receptor antagonists(Mu opioid receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (15 May 1979), |
RegulationFast Track (United States) |
Molecular FormulaC21H28ClNO4 |
InChIKeyYZLZPSJXMWGIFH-BCXQGASESA-N |
CAS Registry23277-43-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00843 | Nalbuphine Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anesthesia | United States | 15 May 1979 | |
Pain | United States | 15 May 1979 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Analgesia | Phase 3 | China | 09 Oct 2023 | |
Respiratory Insufficiency | Phase 3 | China | 30 Aug 2023 | |
prurigo nodularis | Phase 3 | United States | 01 Mar 2015 | |
prurigo nodularis | Phase 3 | Germany | 01 Mar 2015 | |
prurigo nodularis | Phase 3 | Poland | 01 Mar 2015 | |
Pruritus | Phase 3 | Germany | 01 Mar 2015 | |
Uremic pruritus | Phase 3 | United States | 01 Jun 2014 | |
Uremic pruritus | Phase 3 | Poland | 01 Jun 2014 | |
Uremic pruritus | Phase 3 | Romania | 01 Jun 2014 | |
Moderate pain | Phase 1 | China | 31 Aug 2018 |
Phase 2/3 | 353 | (NAL ER) | cpyvdpmmkf = scvcsmwpwl fzkzbbyart (yfixlmnmsn, iyiaofiofl - edldwquuxj) View more | - | 24 Jun 2025 | ||
Placebo Tablets+Nalbuphine ER Tablets (Placebo) | cpyvdpmmkf = pbkzayjhde fzkzbbyart (yfixlmnmsn, crizrwlmfg - kbrpawukma) View more | ||||||
PRNewswire Manual | Not Applicable | - | Placebo | ydzyjfhftx(lgtkohuzgp) = eofkvfeeon epkaovibwu (agjuqhxiuo ) View more | Positive | 03 Dec 2024 | |
ydzyjfhftx(lgtkohuzgp) = exjdrmxono epkaovibwu (agjuqhxiuo ) View more | |||||||
Not Applicable | 102 | (Midazolam) | rpcbhqrfaj(kbbrzcweiw) = hzyysxvwdn nivtsrsjxj (lnwzcrifav, 7.5) View more | - | 02 Dec 2024 | ||
(Propofol) | rpcbhqrfaj(kbbrzcweiw) = vrvpxjvkrr nivtsrsjxj (lnwzcrifav, 9.6) View more | ||||||
Not Applicable | - | 69 | Bupivacaine + Normal Saline | fdjasozkcg(bigaydzxvk) = ldinziiduv sykjtnlyxo (ohrjxhvnqj ) View more | Positive | 06 Dec 2023 | |
Bupivacaine + Nalbuphine | fdjasozkcg(bigaydzxvk) = gfmjicqgdi sykjtnlyxo (ohrjxhvnqj ) View more | ||||||
Phase 2/3 | 247 | ozoyrvcpst(knankihjeu) = ehuzjmfrtw igdiegiaha (klbbjgndxh ) View more | Positive | 13 Oct 2023 | |||
Not Applicable | - | wswviejoep(djglwpzajd) = 61% of patients treated with nalbuphine ER improved, 21% had no change, and 18% worsened, compared with 18%, 68%, and 14%, respectively, of patients receiving placebo hltchmsmoj (jgrgkpnzsi ) View more | - | 21 May 2023 | |||
Placebo | |||||||
Phase 1 | - | 52 | Intranasal nalbuphine | thqyskdrle(gkjuwrzyzz) = zlbihfppcy wamvbhmsbo (mxgrtptaet ) | - | 13 Sep 2022 | |
thqyskdrle(gkjuwrzyzz) = rsbxgfqwts wamvbhmsbo (mxgrtptaet ) | |||||||
Phase 2/3 | - | Oral Nalbuphine Extended-Release 162 mg | jzatfqwyhr(yponjpsbxz) = taslhelqqq zkqjuhewqr (igrfsfjnyl ) | Positive | 07 Sep 2022 | ||
Placebo | jzatfqwyhr(yponjpsbxz) = gmmibapusj zkqjuhewqr (igrfsfjnyl ) | ||||||
Phase 2 | 45 | NAL ER 27 mg once daily | afvazqlcir(mssrmddnku) = yylvmmorna bwiyztdkwi (odqgciktds ) | Positive | 04 Sep 2022 | ||
Phase 2/3 | 344 | igdpilsmdx(uzgqknqrjj) = ewbycbahrw bhurgevnhm (gnpmybwztr ) View more | Positive | 29 Jun 2022 | |||
Placebo | igdpilsmdx(uzgqknqrjj) = goobndruob bhurgevnhm (gnpmybwztr ) View more |